Ultragenyx Pharmaceutical RARE reported its Q2 earnings results on Thursday, July 28, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Ultragenyx Pharmaceutical missed estimated earnings by 29.14%, reporting an EPS of $-2.26 versus an estimate of $-1.75.
Revenue was up $2.37 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.43 which was followed by a 13.38% drop in the share price the next day.
Here's a look at Ultragenyx Pharmaceutical's past performance:
Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
---|---|---|---|---|
EPS Estimate | -1.76 | -1.34 | -1.41 | -1.36 |
EPS Actual | -2.19 | -1.79 | -1.08 | -1.81 |
Revenue Estimate | 83.65M | 83.79M | 81.55M | 85.03M |
Revenue Actual | 79.94M | 83.39M | 81.65M | 86.97M |
To track all earnings releases for Ultragenyx Pharmaceutical visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.